MedTrace Logo

EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD

NCT06321887 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-20

No results posted yet for this study

Summary

Iron deficiency anaemia (IDA) is common in inflammatory bowel disease (IBD). However, although iron is commonly prescribed, the amount of elemental iron needed to achieve clinical efficacy, and the optimal method of supplementation, are under debate. This pilot study aims to investigate the efficacy and safety of low dose and standard dose oral iron preparations for the treatment of IDA in patients with IBD.

Conditions

Interventions

DRUG

Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)

Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).

DRUG

Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)

Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).

DRUG

Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)

Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).

Sponsors & Collaborators

  • Liverpool University Hospitals NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • T Conley · Liverpool University Foundation NHS Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2024-10-01
Completion
2025-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06321887 on ClinicalTrials.gov